Claims
- 1. A compound of formula IA ##STR13## or pharmaceutically acceptable salts thereof wherein R.sub.1 is methyl, ethyl, cyclopropyl, or dichloromethyl.
- 2. A compound of formula IB ##STR14## or pharmaceutically acceptable salts thereof wherein R.sub.1 is ethyl, cyclopropyl, or dichloromethyl.
- 3. A compound of formula II ##STR15## or pharmaceutically acceptable salts thereof wherein R.sub.4 is ethyl, or dichloromethyl.
- 4. compound which is
- a. (-)-N-[[(5S)-3-[3-fluoro-4-(cis-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide,
- b. (-)-N-[[(5S)-3-[3-fluoro-4-(cis-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]propanamide,
- c. (-)-N-[[(5S)-3-[3-fluoro-4-(cis-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]cyclopropanecarboxamide,
- d. (-)-2,2-dichloro-N-[[(5S)-3-[3-fluoro-4-(cis-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide,
- e. (-)-N-[[(5S)-3-[3-fluoro-4-(trans-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]propanamide,
- f. (-)-N-[[(5S)-3-[3-fluoro-4-(trans-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]cyclopropanecarboxamide,
- g. (-)-2,2-dichloro-N-[[(5S)-3-[3-fluoro-4-(trans-tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide,
- h. (-)-N-[[(5S)-3-[3-fluoro-4-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]propanamide, or
- i. (-)-2,2-dichloro-N-[[(5S)-3-[3-fluoro-4-(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide.
- 5. A method for treating microbial infections in humans and other warm blooded animals which comprises administering to a patient in need thereof an effective amount of a compound of claim 1, 2 or 3.
- 6. The method of claim 5 wherein said compound of is administered orally, parenterally, transdermally, or topically in a pharmaceutical composition.
- 7. The method of claim 5 wherein said compound is administered in an amount of from about 0.1 to about 100 mg/kg of body weight/day.
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of the following provisional applications: U.S. Ser. No. 60/067,830 filed Dec. 5, 1997; U.S. Ser. No. 60/089,498 filed Jun. 16, 1998; and U.S. Ser. No. 60/100,185 filed Sep. 14, 1998.
US Referenced Citations (4)
Number |
Name |
Date |
Kind |
4948801 |
Carlson et al. |
Aug 1990 |
|
5130316 |
Carlson et al. |
Jul 1992 |
|
5254577 |
Carlson et al. |
Oct 1993 |
|
5523403 |
Barbachyn |
Jun 1996 |
|
Foreign Referenced Citations (4)
Number |
Date |
Country |
0352781 |
Jan 1990 |
EPX |
WO9309103 |
May 1993 |
WOX |
WO9709328 |
Mar 1997 |
WOX |
WO9730995 |
Aug 1997 |
WOX |
Non-Patent Literature Citations (6)
Entry |
W. Weyler and JI Salach, J. of Biol. Chem., 260(24):13199-13207 (1985). |
JI Salach and W Weyer, Methods in Enzymology, 142:627-631 (1987). |
MJ Krueger and TP Singer, Analytical Biochem., 214:116-123 (1993). |
KF Tipton and TP Singer, Biochem. Pharm., 46(8):1311-1316 (1993). |
P. Flaherty, et al., J. Med. Chem, 39:4756-4761 (1996). |
JJP Zhou, et al., Analytical Biochem., 234:9-12 (1996). |